Weight Loss Drugs Linked to Eye Risks

Emerging evidence suggests that widely used GLP-1 receptor agonists, prescribed for obesity and type-2 diabetes, may pose risks to eye health. These medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have shown effectiveness in managing blood sugar and weight. However, ophthalmologists are noting a potential link to an initial worsening of diabetic retinopathy.

In rare cases, these drugs have also been associated with non-arteritic ischemic optic neuropathy (NAION), an "eye stroke" causing sudden vision loss. Experts theorize that rapid blood sugar reduction might temporarily affect retinal and optic nerve blood flow. While long-term data is still being gathered, global health agencies acknowledge NAION as a rare potential adverse effect.

The risk appears elevated in patients with existing diabetic retinopathy, hypertension, or sleep apnea. Medical professionals stress the importance of thorough pre-treatment evaluations, assessing both systemic and ocular health. High-risk patients may require closer monitoring, including regular retinal examinations.

Doctors advocate for a collaborative approach between endocrinologists and ophthalmologists to manage these risks effectively. They strongly advise against self-medication and emphasize that treatment with these drugs should only occur under proper medical supervision. Patients with uncontrolled diabetes or advanced retinopathy are considered most vulnerable to potential visual disturbances.